Fibrosis
Conditions
Brief summary
The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of the fibrosis. Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical conditions including the treatment of delayed radiation injuries (soft tissue and bony radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation tissue and produces angiogenesis maintained after use.
Detailed description
Patients with head and neck tumors often present superficial radiation induced fibrosis and other late complications of radiotherapy that can seriously affect their quality of life. The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of the fibrosis. Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical conditions including the treatment of delayed radiation injuries (soft tissue and bony radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation tissue and produces angiogenesis maintained after use. Both treatments in combination could produce a synergistic effect because the angiogenesis induced by hyperbaric oxygen therapy allow better access to drugs to the injury. The magnetic resonance, provides data of the fibrosis and other side effects of radiotherapy.
Interventions
DRUGpentoxifylline with tocopherol
Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
OTHERpentoxifylline+tocopherol + Hyperbaric Oxygen Therapy
pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months. Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment.
Sponsors
Instituto Médico Tinerfeño IMETISA
Hospital Universitario de Canarias
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Over 18 years and under 70 years old. 2. Patients who have received radiotherapy after being diagnosed with cancer of upper aerodigestive tract, and have skin toxicity grade II or higher. 3. Follow-up for at least a year after the radiation treatment is completed. 4. Absence of tumor at the time of recruitment. 5. Patients with the capacity to give informed consent
Exclusion criteria
1. Allergy or hypersensitivity to Pentoxifylline or others xanthines, or to Tocopherol (vitamin E). 2. Patients taking oral anticoagulants (acenocoumarol, warfarin). 3. Known hemorrhagic/coagulation disorder. 4. Vitamin K deficiency due to any cause. 5. Use of estrogens oral contraceptives. 6. Serious bleeding or extensive retinal hemorrhage. 7. Ischaemic heart diseases, including recent Myocardial Infarction. 8. Serious cardiac arrhythmia. 9. Severe liver disease. 10. Severe renal failure (creatinine clearance \<30 mL/min). 11. Hypotension. 12. Patients with metal objects or electronic devices such as cardiac pacemakers, artificial heart valves or cochlear implants, or any other contraindication for MRI 13. Contraindication for Hyperbaric oxygen therapy. 14. Patients with mobility problems. 15. Female patients who are pregnant or lactating 16. Any other situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in skin fibrosis measured by MRI | From baseline to 6 month of starting treatment | The change is calculated as the latest time point (6 months) minus the earliest time point (baseline) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical assessment of the radiation late (delayed) toxicity for mucosal membranes, salivary glands, larynx and skin by the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale) | Baseline and 6 months | The change is calculated as the latest time point (6 months) minus the earliest time point (baseline) |
Countries
Spain
Contacts
Primary ContactClaudio Otón, MD
Outcome results
None listed